Wei Zhang

Wei Zhang


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

15 July 2020 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
WZWei Zhang
Wei Zhang
LZLiang Zhu
Liang Zhu
GYGuowei Yang
Guowei Yang
BZBo Zhou
Bo Zhou
JWJianhua Wang
Jianhua Wang
RLRong Liu
Rong Liu
Increasing evidence shows that circular RNAs (circRNAs) play a regulatory role in cancer. In the present study, we aimed to investigate the characteristics and effects of hsa_circ_0026134 in hepatocellular carcinoma (HCC). We investigated hsa_circ_0026134 expression in 20 pairs of clinical tissues from HCC patients; expression of hsa_circ_0026134 in different cell lines; effect of hsa_circ_0026134 on proliferation and invasion of HCC cell lines; and the regulatory mechanisms and interactions among hsa_circ_0026134, miR-127-5p, tripartite motif-containing protein 25 (TRIM25) and insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3). hsa_circ_0026134 expression was increased in HCC samples and cell lines. Down-regulation of hsa_circ_0026134 attenuated HCC cell proliferation and metastatic properties. Micro (mi)RNA (miR)-127-5p was sponged by hsa_circ_0026134. Rescue experiments indicated that inhibition of miR-127-5p expression promoted cell proliferation and invasion even after hsa_circ_0026134 silencing. TRIM25 and IGF2BP3 were targets of miR-127-5p. Overexpression of TRIM25 or IGF2BP3 promoted cell proliferation and invasion in cells overexpressing miR-127-5p. Down-regulation of hsa_circ_0026134 suppressed TRIM25- and IGF2BP3-mediated HCC cell proliferation and invasion via promotion of miR-127-5p expression, which have been confirmed by luciferase reporter assay. The present study provides a new treatment target for HCC.

12 October 2024 in BMC Surgery
Verified
Journal Article
Open access
PDF file
YCYiheng Cai
Yiheng Cai
ZFZhuoyang Fan
Zhuoyang Fan
GYGuowei Yang
Guowei Yang
DZDanyang Zhao
Danyang Zhao
LSLiting Shan
Liting Shan
RLRong Liu
Rong Liu
This study aimed to assess the safety and efficacy of percutaneous transhepatic cholangiography drainage (PTCD) and endoscopic retrograde cholangiopancreatography (ERCP) in palliative drainage and preoperative biliary drainage for treating malignant obstructive jaundice (MOJ). A total of 520 patients with MOJ who underwent PTCD or ERCP were enrolled and classified into palliative drainage group and preoperative biliary drainage group. Baseline characteristics, liver function, blood routine, complications were compared among the groups. The technical success rates for PTCD and ERCP in palliative group were 97.1% and 85.9%. In palliative drainage group, PTCD had higher levels of total bilirubin (TB) reduction (53.0 (30.0,97.0) vs. 36.8 (17.9,65.0), p < 0.001) and direct bilirubin (DB) reduction (42.0 (22.0,78.5) vs. 28.0 (12.0,50.8), p = 0.001) than ERCP. However, PTCD was associated with higher rates of drainage tube displacement (20 cases, 11.8%), while ERCP had a higher incidence of biliary infection (39 cases, 22.8%) and pancreatitis (7 cases, 4.1%). In preoperative drainage group, PTCD achieved a 50% reduction in total bilirubin faster than ERCP (7.1 days vs. 10.5 days). And the time from palliation of jaundice to surgery was 24.2 days in PTCD group and 35.7 days in ERCP group, a statistically significant difference (Student’s t test, p = 0.017). Both PTCD and ERCP could improve liver function for MOJ patients. PTCD seems to offer better outcomes in jaundice reduction and liver function improvement in palliative drainage, but requires careful postoperative management. In preoperative biliary drainage, PTCD may be a better preoperative bridge to improve liver function and control infection.

7 November 2022 in Polymers
Verified
Journal Article
Open access
PDF file
RWRuizhi Wang
Ruizhi Wang
NDNan Du
Nan Du
LJLiang Jin
Liang Jin
WCWufei Chen
Wufei Chen
ZMzhuangxuan ma
zhuangxuan ma
MLming Li
ming Li
Bladder cancer and prostate cancer are the most common malignant tumors of the genitourinary system. Conventional strategies still face great challenges of high recurrence rate and severe trauma. Therefore, minimally invasive photothermal therapy (PTT) has been extensively explored to address these challenges. Herein, fluorescent Au nanoparticles (NPs) were first prepared using glutathione as template, which were then capped with SiO2 shell to improve the biocompatibility. Next, Au nanoclusters were deposited on the NPs surface to obtain Au@SiO2@Au NPs for photothermal conversion. The gaps between Au nanoparticles on their surface could enhance their photothermal conversion efficiency. Finally, hyaluronic acid (HA), which targets cancer cells overexpressing CD44 receptors, was attached on the NPs surface via 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) chemistry to improve the accumulation of NPs in tumor tissues. Photothermal experiments showed that NPs with an average size of 37.5 nm have a high photothermal conversion efficiency (47.6%) and excellent photostability, thus exhibiting potential application as a PTT agent. The temperature of the NPs (100 μg·mL−1) could rapidly increase to 38.5 °C within 200 s and reach the peak of 57.6 °C with the laser power density of 1.5 W·cm−2 and irradiation time of 600 s. In vivo and in vitro PTT experiments showed that the NPs have high biocompatibility and excellent targeted photothermal ablation capability of cancer cells. Both bladder and prostate tumors disappeared at 15 and 18 d post-treatment with HA-Au@SiO2@Au NPs, respectively, and did not recur. In summary, HA-Au@SiO2@Au NPs can be used a powerful PTT agent for minimally invasive treatment of genitourinary tumors.

19 August 2023 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
LSLinlin Shi
Linlin Shi
DLDanni Li
Danni Li
QTQianqian Tong
Qianqian Tong
GJGuorong Jia
Guorong Jia
XLXiaohong Li
Xiaohong Li
XLXiao Li
Xiao Li
Background: The excellent physicochemical and biomedical properties make silk fibroin (SF) suitable for the development of biomedical materials. In this research, the silk fibroin microspheres (SFMS) were customized in two size ranges, and then carried gold nanoparticles or doxorubicin to evaluate the performance of drug loading and releasing. Embolization efficiency was evaluated in rat caudal artery and rabbit auricular artery, and the in vivo distribution of iodinated SFMS (125I/131I-SFMS) after embolization of rat hepatic artery was dynamically recorded by SPECT. Transhepatic arterial radioembolization (TARE) with 131I-SFMS was performed on rat models with liver cancer. The whole procedure of selective internal radiation was recorded with SPECT/CT, and the therapeutic effects were evaluated with 18 F-FDG PET/CT. Lastly, the enzymatic degradation was recorded and followed with the evaluation of particle size on clearance of sub-micron silk fibroin. Results: SFMS were of smooth surface and regular shape with pervasive pores on the surface and inside the microspheres, and of suitable size range for TAE. Drug-loading functionalized SFMS with chemotherapy or radio-sensitization, and the enhanced therapeutic effects were proved in treating HUH-7 cells as lasting doxorubicin release or more lethal radiation. For artery embolization, SFMS effectively blocked the blood supply; when 131I-SFMS serving as the embolic agent, the good labeling stability and embolization performance guaranteed the favorable therapeutic effects in treating in situ liver tumor. At the 5th day post TARE with 37 MBq/3 mg 131I-SFMS per mice, tumor activity was quickly inhibited to a comparable glucose metabolism level with surrounding normal liver. More importantly, for the fragments of biodegradable SFMS, smaller sized SF (< 800 nm) metabolized in gastrointestinal tract and excreted by the urinary system, while SF (> 800 nm) entered the liver within 72 h for further metabolism. Conclusion: The feasibility of SFMS as degradable TARE agent for liver cancer was primarily proved as providing multiple therapeutic potentials. Graphical

11 January 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
ZFZhuoyang Fan
Zhuoyang Fan
GYGuowei Yang
Guowei Yang
RLRongkui Luo
Rongkui Luo
XQXudong Qu
Xudong Qu
XYXiaodan Ye
Xiaodan Ye
RLRong Liu
Rong Liu
Introduction: Heat ablation is one of the key modalities in treating liver cancer, yet the residual cancer tissues suffering sublethal heat treatment possess a potential for increased malignancy. This study conducts a comprehensive analysis of cellular dynamics, metabolic shifts, and macrophage polarization within the tumor microenvironment following sublethal heat treatment.Methods: We observed significant acidification in tumor cell supernatants, attributed to increased lactic acid production. The study focused on how this pH shift, crucial in tumor progression and resistance, influences macrophage polarization, especially towards the M2 phenotype known for tumor-promoting functions. We also examined the upregulation of MCT1 expression post sublethal heat treatment and its primary role in lactic acid transport.Results: Notably, the study found minimal disparity in MCT1 expression between hepatocellular carcinoma patients and healthy liver tissues, highlighting the complexity of cancer biology. The research further revealed an intricate relationship between lactic acid, MCT1, and the inhibition of macrophage pyroptosis, offering significant insights for therapeutic strategies targeting the tumor immune environment. Post sublethal heat treatment, a reduction in paraspeckle under lactic acid exposure was observed, indicating diverse cellular impacts. Additionally, PKM2 was identified as a key molecule in this context, with decreased levels after sublethal heat treatment in the presence of lactic acid.Discussion: Collectively, these findings illuminate the intertwined mechanisms of sublethal heat treatments, metabolic alterations, and immune modulation in the tumor milieu, providing a deeper understanding of the complex interplay in cancer biology and treatment.